[Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in the first complete remission].

Abstract

The treatment outcomes for adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) have improved with the introduction of pediatric protocols. On assessing long-term survivors of chemotherapy who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), it was found that these patients had good performance status and few complications. Therefore, in the first complete remission (1CR) of ALL, allo-HSCT is indicated for patients in whom the results of chemotherapy are predicted to be poor. In adolescent and young adult (AYA) patients with ALL, allo-HSCT is recommended in the 1CR if end of consolidation measurable residual disease (MRD) is positive. In adults with ALL (non-AYA patients), if end of induction MRD is negative, chemotherapy should be continued and allo-HSCT is not recommended. In the future, it is necessary to perform a comprehensive evaluation of individual patients that considers MRD, as well as the initial tumor burden and biological features of leukemic cells.

• Authors: Koji Nagafuji
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 64 Issue 9 Pg. 1144-1151 ( 2023) ISSN: 0485-1439 [Print] Japan
• PMID: 37899194 (Publication Type: English Abstract, Journal Article)

Topics

• Adolescent
• Young Adult
• Humans
• Child
• Philadelphia Chromosome
• Treatment Outcome
• Remission Induction
• Hematopoietic Stem Cell Transplantation
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics, therapy, pathology)
• Neoplasm, Residual
• Retrospective Studies